Top

Clinical Rheumatology

Published in:

28-04-2023 | Systemic Lupus Erythematosus | LETTER TO THE EDITOR

Folic acid in systemic lupus erythematosus – a new aspect

Authors: Kalina Nikolova-Ganeva, Andrey Tchorbanov

Published in: Clinical Rheumatology | Issue 6/2023

Excerpt

Dear Editor, …

Lucock M (2000) Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 71:121–138. https://doi.org/10.1006/mgme.2000.3027CrossRefPubMed

Mikkelsen K, Apostolopoulos V (2019) Vitamin B12, Folic Acid, and the Immune System, In: Nutrition and Immunity 103–114. Mahmoudi, M., Rezaei, N. (eds) Springer, Cham

Nikolova-Ganeva K, Bradyanova S, Manoylov I, Boneva G, Tchorbanov A (2022) Methyl- rich diet ameliorates lupus-like disease in MRL/lpr mice. Immunobiology 227:152282. https://doi.org/10.1016/j.imbio.2022.152282

Nikolova-Ganeva K, Vasilev V, Kerezieva S, Tchorbanov A (2023) Impact of folic acid on regulatory B lymphocytes from patients with systemic lupus erythematosus in vitro. Int J Rheum Dis 26:298–304. https://doi.org/10.1111/1756-185X.14496CrossRefPubMed

Mauri C, Menon M (2017) Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest 127:772–779. https://doi.org/10.1172/JCI85113CrossRefPubMedPubMedCentral

Cham CM, Ko K, Niewold TB (2012) Interferon regulatory factor 5 in the pathogenesis of systemic lupus erythematosus. Clin Dev Immunol 2012:780436. https://doi.org/10.1155/2012/780436

Guiteras J, Ripoll É, Bolaños N, De Ramon L, Fontova P, Lloberas N et al (2021) The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis. Mol Ther Nucleic Acids 24:807–821. https://doi.org/10.1016/j.omtn.2021.03.019CrossRefPubMedPubMedCentral

Li S, Wu J, Zhu S, Liu YJ, Chen J (2017) Disease-associated plasmacytoid dendritic cells. Front Immunol 8:1268. https://doi.org/10.3389/fimmu.2017.01268CrossRefPubMedPubMedCentral

Rönnblom L, Leonard D (2019) Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 6:e000270. https://doi.org/10.1136/lupus-2018-000270

10.

Chow KT, Wilkins C, Narita M, Green R, Knoll M, Loo YM, Gale M Jr (2018) Differential and Overlapping Immune Programs Regulated by IRF3 and IRF5 in Plasmacytoid Dendritic Cells. J Immunol 201:3036–3050. https://doi.org/10.4049/jimmunol.1800221CrossRefPubMed

11.

Uyeda MJ, Freeborn RA, Cieniewicz B, Romano R, Chen PP, Liu JM et al (2021) BHLHE40 regulates IL-10 and IFN-γ production in T cells but does not interfere with human type 1 regulatory T cell differentiation. Front Immunol 12:683680. https://doi.org/10.3389/fimmu.2021.683680

12.

Rauschmeier R, Reinhardt A, Gustafsson C, Glaros V, Artemov AV, Dunst J et al (2022) Bhlhe40 function in activated B and TFH cells restrains the GC reaction and prevents lymphomagenesis. J Exp Med 219:e20211406. https://doi.org/10.1084/jem.20211406

13.

Hagberg N, Rönnblom L (2015) Systemic lupus erythematosus–A Disease with A dysregulated type I interferon system. Scand J Immunol 82:199–207. https://doi.org/10.1111/sji.12330CrossRefPubMed

14.

Chyuan IT, Tzeng HT, Chen JY (2019) Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. Cells 8:963. https://doi.org/10.3390/cells8090963CrossRefPubMedPubMedCentral

15.

Dörner T, Tanaka Y, Petri MA, Smolen JS, Wallace DJ, Dow ER et al (2020) Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Sci Med 7:e000424. https://doi.org/10.1136/lupus-2020-000424

16.

Mölzer C, Wilson HM, Kuffova L, Forrester JV (2021) A Role for Folate in Microbiome-Linked Control of Autoimmunity. J Immunol Res 9998200. https://doi.org/10.1155/2021/9998200

17.

Zhang L, Qing P, Yang H, Wu Y, Liu Y, Luo Y (2021) Gut microbiome and metabolites in systemic lupus erythematosus: link, mechanisms and intervention. Front Immunol. 12:686501. https://doi.org/10.3389/fimmu.2021.686501

18.

La Cava A (2019) The influence of diet and obesity on gene expression in SLE. Genes (Basel) 10:405. https://doi.org/10.3390/genes10050405CrossRefPubMed

19.

Rossi M, Amaretti A, Raimondi S (2011) Folate production by probiotic bacteria. Nutrients 3:118–134. https://doi.org/10.3390/nu3010118CrossRefPubMedPubMedCentral

20.

Kwon HK, Lee CG, So JS, Chae CS, Hwang JS, Sahoo A et al (2010) Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci USA 107:2159–2164. https://doi.org/10.1073/pnas.0904055107CrossRefPubMedPubMedCentral

21.

So JS, Lee CG, Kwon HK, Yi HJ, Chae CS, Park JA et al (2008) Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol 46:172–180. https://doi.org/10.1016/j.molimm.2008.07.038CrossRefPubMed

Title: Folic acid in systemic lupus erythematosus – a new aspect
Authors: Kalina Nikolova-Ganeva
Andrey Tchorbanov
Publication date: 28-04-2023
Publisher: Springer International Publishing
Keywords: Systemic Lupus Erythematosus
Folic Acid
Epigenetics
Published in: Clinical Rheumatology / Issue 6/2023
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-023-06604-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2023

The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis

Categorization of patients with systemic lupus erythematosus using disease activity, patient-reported outcomes, and transcriptomic signatures

AIM2 and NLRC4-driven inflammasome activation in adult-onset Still’s disease and the preliminary therapeutic effect exploration of carboxyamidotriazole

Dyslipidemia is associated with inflammation and organ involvement in systemic lupus erythematosuss

Can radiomics replace the SPARCC scoring system in evaluating bone marrow edema of sacroiliac joints in patients with axial spondyloarthritis?

Associations of microcirculation damage on nailfold capillaroscopy with supra-aortic severe ischemic events in patients with Takayasu arteritis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials